Plasma concentration of elastase-alpha 1-proteinase inhibitor complex in surfactant-treated preterm neonates with respiratory distress syndrome

Abstract

P Pl la as sm ma a c co on nc ce en nt tr ra at ti io on n o of f e el la as st ta as se e--α 1 1 --p pr ro ot te ei in na as se e i in nh hi ib bi it to or r c co om mp pl le ex x i in n s su ur rf fa ac ct ta an nt t--t tr re ea at te ed d p pr re et te er rm m n ne eo on na at te es s w wi it th h r re es sp pi ir ra at to or ry y d di is st tr re es ss s s sy yn nd dr ro om me e Since elastase-α 1 -proteinase inhibitor (E-α 1 -PI) has proved to be a sensitive indicator of intravascular PMN activation, we studied E-α 1 -PI plasma concentration in preterm neonates during the treatment of RDS with a bovine surfactant preparation (group I: n=23). Results were compared with those from a retrospective control group treated by ventilation alone (group II: n=13), and with a reference group of 92 newborns (group III). From these results, it is concluded that surfactant may trigger a transient, mainly local, inflammatory response, reflected by increased levels of E-α 1 -PI, and may exert a dose-related pathogenic influence on the course and prognosis of RDS. Under these conditions, the validity of E-α 1 -PI for the diagnosis of early-onset septicaemia may be limited.

Impact of adalimumab on work participation in rheumatoid arthritis: comparison of an open-label extension study and a registry-based control group

“…In scenarios where randomisation is not possible or practical, use of separate control groups is a well-established technique. Separate control groups have been used for clinical studies in a diverse range of therapeutic areas 48 – 51. A separate control group was used in a study of RA that evaluated the impact of etanercept on employment 30.…”